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Four cationic ruthenium(II) complexes with the formula [Ru(η5-C5H5)(PPh3)2]
+,w i t hL = 5-phenyl-1H-tetrazole (TzH)
1, imidazole (ImH) 2, benzo[1,2-b;4,3-b
 ] dithio-phen-2-carbonitrile (Bzt) 3, and [5-(2-thiophen-2-yl)-vinyl]-thiophene-2-
carbonitrile] (Tvt) 4 were prepared and characterized in view to evaluate their potentialities as antitumor agents. Studies by
Circular Dichroism indicated changes in the secondary structure of ct-DNA. Changes in the tertiary structure of pBR322 plasmid
DNA were also observed in gel electrophoresis experiment and the images obtained by atomic force microscopy (AFM) suggest
strong interaction with pBR322 plasmid DNA; the observed decreasing of the viscosity with time indicates that the complexes
do not intercalate between DNA base pairs. Compounds 1, 2,a n d3 showed much higher cytotoxicity than the cisplatin against
human leukaemia cancer cells (HL-60 cells).
1.Introduction
The driving force for the studies of metal-based drugs in the
treatment of cancer has been certainly the enormous impact
of cisplatin. This platinum complex continues to be applied
in 50%–70% of all cancer patients, usually in combination
with other drugs [1]. Nevertheless, the undesirable side-
eﬀects of cisplatin, its inactivity against many cancer cell
lines and tumors metastasis [2] has stimulated the search
for new eﬀective drugs, in the ﬁeld of nonplatinum-based
anticancer drugs [3–5]. Although the promising results for
compounds derived of several metals such as titanium [6],
iron[7],gold[8],gallium[9],andtin[10],itappearsthatthe
ruthenium derivatives occupy already a prominent position
due to success of [ImH][trans-RuCl4(DMSO)Im], NAMI-A,
[ImH][trans-RuCl4Im2](Im=imidazole)and(Hind)[trans-
RuCl4(ind)2], and KP1019, (ind = indazole) in progressing
through clinical trials [11–13] .T h em a i nd r a w b a c ko f
the coordination compounds concerning clinical trials has
been related to their instability and complicated ligand
exchange chemistry. Thus, organometallic ﬁeld appeared as
an attractive ﬁeld to provide organoruthenium complexes as
suitable drug candidates. Under this perspective, the studies
already reported are quite promising, in some families of
ruthenium η6-arene derivatives which were found active
against hypotoxic tumor cells [14, 15], in vitro breast and
coloncarcinomacells[16,17],inhibitionofthegrowthofthe
human ovarian cancer cells line A2780 [18], and mammary2 Bioinorganic Chemistry and Applications
cancer cell line [19]. Studies on π-arene compounds have
been recently reviewed [20, 21]. Although the literature is
scarce in studies concerning ruthenium η5-cyclopentadienyl
(RuCp) derivatives, it appears of interest the results already
found for compounds containing the “CpRu(CO)” fragment
and pyridocarbazole derived ligands which revealed to be
potent and selective inhibitors forprotein kinases GSK-3 and
Pim-1 [22].
Our approach in this ﬁeld has been the study of
compoundsderivedof“RuCp”containingN-heteroaromatic
sigma coordinated ligands [23] and CpRu(η6-arene) where
the structures of the η6-arene ligands were based on two or
three fused rings [24]. Our studies by AFM revealed a strong
interaction with the plasmid pBR322 DNA. The obtained
images showed compaction, supercoiling and kinks in the
DNAforms.CircularDichroismandviscositymeasurements
on ct-DNA also indicated that the complexes interact
with the double helix. Compounds 1, 2,a n d3 showed
much higher cytotoxicity than the cisplatin against human
leukaemia cancer cells (HL-60 cells). The compound 4 gave
al o w e rI C 50 value than cisplatin at 24 hours and a similar
value at 72 hours. Moreover, some other CpRu compounds
previouslystudiedshowedalsosigniﬁcanteﬀectoftoxicityin
Lovo and MiaPaCa cells in the nanomolar range [23].
2. Results andDiscussion
Ourcontinuingstudiesonthefamilyof[Ru(η5-C5H5)(PP)]+
fragment containing complexes in view of studies of cytotox-
icity led us to the synthesis of two new cationic complexes of
the type [Ru(η5-C5H5)(PPh3)2 L]+ where the metal atom is
σ bound to the donor nitrogen atom of the heteroaromatic
ligands L = 5-phenyl-1H-tetrazole (TzH) and imidazole
(ImH).
Having in mind that diﬀerent structures of the coor-
dinated molecule L,c a nl e a dt od i ﬀerent interactions with
DNA, two other known compounds were also prepared
and studied. One of these compounds presents the ligand
L as a wide planar system based on a thiophene-benzene-
thiophene ortho-fused rings structure, namely, benzo[1, 2-
b; 4, 3-b
 ]dithio-phen-2-carbonitrile [25]( Bzt), while the
ligand of the other compound is based on a long planar
structure, namely, [5-(2-thiophen-2-yl)-vinyl]-thiophene-2-
carbonitrile (Tvt)[ 26].
The complexes [Ru(η5-C5H5) (PPh3)2 L][PF6]w i t hL=
5-phenyl-1H-tetrazole (1) and imidazole (2) were prepared
by the general method of halide abstraction of [Ru(η5-
C5H5)(PPh3)2Cl] with thallium hexaﬂuorophosphate in the
presence of the adequate ligand (Scheme 1). The starting
material [Ru(η5-C5H5)(PPh3)2Cl] was prepared according
to the literature [27] and the mentioned ligands were used
as purchased. Compounds [RuCp(PPh3)2(Bzt)][PF6] 3 and
[RuCp(PPh3)2(Tvt)][PF6] 4 and the corresponding ligands
were prepared and characterised following our previous
publications [25, 26].
Compounds were obtained in good yields and recrystal-
lized by slow diﬀusion of diethyl ether in dichloromethane
solutions. The new compounds were fully characterized by
FT-IR, 1H, 13C, and 31P NMR spectroscopies; elemental
analyses were in accordance with the proposed formulations.
2.1. Spectroscopic Studies. The main feature on the 1HN M R
chemical shifts of the coordinated ligands is a general
trend of shielding of the protons of the heteroaromatic
rings with special relevance for the proton adjacent to the
N coordinated atom. This eﬀect, also observed on other
related compounds [28], might be due to the inﬂuence
of the organometallic moiety on the ring current of the
heteroaromatic ligands.
Interestingly,compound2showsonesignalat11.53ppm,
integrating perfectly for one proton and attributed to the
NH proton of imidazole which, in the same solvent, could
not be found in the free imidazole. This observation is
in good agreement with the observed shielding on the
other protons of the heteroaromatic ring upon coordination.
Accordingly, 13C NMR spectra showed a general deshielding
upto13.6ppmonthecarbonsofthecoordinatedligand,this
eﬀect being more pronounced on compound 2.
The 31P NMR spectra revealed equivalency of both P
atoms of the phosphines, with a singlet at ∼42ppm, with the
expected deshielding upon coordination to the metal centre,
and the septet relative to the counter ion PF6
− at −144ppm.
The FT-IR spectra typically showed the characteristic
bands of the Cp and Ph aromatic rings in the region 3040–
3080cm−1, and the characteristic bands of the PF6 anion at
840 and 560cm−1.
2.2. Electrochemical Studies. The electrochemical properties
of the ligands and the new Ru(II) complexes 1 and 2
were examined by cyclic voltammetry in acetonitrile and
dichloromethane solutions (1 × 10−3 M) using 0.2M tetra-
butylammonium hexaﬂuorophosphate (TBAPF6)a ss u p -
porting electrolyte. The redox potentials measured at the
scan rate of 0.2V/s are reported in Table 1. The electrochem-
ical behaviour of complexes 3 and 4 was already reported
[25, 26].
The cyclic voltammogram of TzH ligand is characterized
b yo n ei r r e v e r s i b l er e d o xp r o c e s sa tEpa =− 0.69V with
the corresponding reductive wave at Epc =− 0.99V in
acetonitrile, being these values of −0.50 V and −0.80V,
respectively, in dichloromethane. Due to the insolubility
of ImH in dichloromethane, its electrochemistry was only
studied in acetonitrile and revealed two irreversible pro-
cesses, one oxidation at Epa = +1.42V without the cathodic
counterpartandonereductionatEpc =− 0.88Vwithoutthe
corresponding anodic complement.
Both complexes were electroactive in the sweep range
±1.8V and displayed one-electron quasi-reversible coupled
redox wave in dichloromethane solution, as showed in
Figure 1. The oxidative couple exhibited by the complexes
1 and2withE 1/2 at1.24and1.06V,respectively,isattributed
to the Ru(II)/Ru(III) redox process in accordance with our
earlier results in some analogous ruthenium compounds
[25, 26, 29], these values being lower than those found
for complexes 3 and 4. At negative potentials, it was not
found any redox process that could be related with theBioinorganic Chemistry and Applications 3
Table 1: Electrochemical data for the [RuCp(PPh3)2L)][PF6]( L= TzH, ImH) complexes and the free ligands in dichloromethane and
acetonitrile.
Dichloromethane
Compound Epa (V) Epc (V) E 1/2 (V) ΔEa (mV) Ic/Ia
TzH −0.50 −0.80 — — —
ImHb —— — ——
1 1.27 1.21 1.24 60 1.0
2 1.10 1.02 1.06 80 1.0
Acetonitrile
Compound Epa (V) Epc (V) E 1/2 (V) ΔEa (mV) Ic/Ia
TzH −0.69 −0.99 — — —
ImH 1.42 — — — —
— −0.88 — — —
1
1.22 — — — —
0.86 — — — —
— −0.70 — — —
2
1.25 — — — —
0.92 — — — —
— −0.47 — — —
aΔE = Epa −Epc; bInsoluble in dichloromethane.
Table 2: IC50 values of ruthenium compounds, and cisplatin against HL-60 cells.
Complex IC50 (μM)
72 hours
IC50 (μM)
24 hours
[Ru(η5-C5H5)(PPh3)2TzH]
+ 1 0.69 ± 0.16 0.95 ± 0.15
[Ru(η5-C5H5)(PPh3)2ImH]
+ 2 0.53 + 0.05 0.57 + 0.09
[Ru(η5-C5H5)(PPh3)2Bdt]
+ 3 0.94 + 0.085 1.46 + 0.25
[Ru(η5-C5H5)(PPh3)2Tvt]
+ 4 2.26 + 0.53 5.89 + 0.67
CDDP 2.15 + 0.1 15.61 + 1.15
ligands.Duringtheelectrochemicalstudyofcomplex 1some
passivation occurred at the platinum electrode, probably due
to any potential-induced polymerisation processes in this
solvent, originated by the ligand.
The electrochemical behaviour of the studied complexes
inacetonitrilewasquitediﬀerent.Thecyclicvoltammograms
were characterised by one ﬁrst irreversible oxidation process
at Epa = 0.86V and Epa = 0.92V for complexes 1 and 2
appearing a second irreversible oxidation process at Epa =
1.22V for complex 1 and Epa = 1.25V for complex 2.
By analogy with the electrochemistry run in dichloro-
methane, this second anodic wave was attributed to the
oxidation RuII/RuIII for the present studied complexes. In
ordertoidentifythespeciesresponsiblefortheﬁrstoxidation
process, some additional experiments were carried out. It
was postulated that the most likely candidate would be the
cationiccomplex[RuCp(PPh3)2(NCMe)]+,originatedinthe
electrochemical cell, by substitution of the 5-phenyl-1H-
tetrazole and imidazole ligands by the acetonitrile coordina-
tive solvent.
Experiments in the nmr tube, with a sample solution
of compound 2 in CD3CN revealed a slow substitution
of the imidazole ligand by the solvent. In eﬀect, only few
hours later a signiﬁcant amount of the new compound
was found in the 1Ha n d31P NMR nmr spectra, being
a conversion of about 90% found only 72 hours later.
Although this slow substitution process is not likely to occur
at the electrochemistry time scale, the electrochemistry of
compound [RuCp(PPh3)2(NCMe)][PF6], prepared in the
benchforthispurpose,wasstudiedinthesameexperimental
conditions of compounds 1 and 2 to discard this hypothesis.
The voltammogram only revealed one oxidative process
occurring at ∼ Epa = 1.48V, attributed to the oxidation
RuII/RuIII.
Although no further experiments were carried out, it
seems that one possible explanation for the waves occurring
at Epa = 0.86V and Epa = 0.92V for complexes 1 and 2,
can be an irreversible oxidation occurring at the coordinated
ligands.
The ligand-based reduction waves were found at Epc =
−0.70V and −0.47V for complexes 1 and 2,r e s p e c t i v e l y ,
while for the corresponding free ligands the values were
Epc =− 0.99V and −0.88V. Thus, the corresponding poten-
tials were in the order TzH < ImH < 1 < 2, with the ruthe-
nium complexes showing the most facile reductions. The
stability of the pair RuII/RuIII showed by the electrochemical4 Bioinorganic Chemistry and Applications
Table 3: Percentage of HL-60 cells in each state after treatment with metal complexes at IC50 concentration for 24 hours of incubation.
Treatment (IC50 24 hours μM) % vital cells (R1) % apoptotic cells (R2) % dead cells (R3) % damaged cells (R4)
Control 91.1 4.8 3.9 0.2
CDDP 55.0 40.7 3.6 0.7
[Ru(η5-C5H5)(PPh3)2TzH]
+ 1 74.7 19.9 5.0 0.4
[Ru(η5-C5H5)(PPh3)2ImH]
+ 2 62.6 29.8 7.3 0.3
[Ru(η5-C5H5)(PPh3)2Bdt]
+ 3 60.0 20.8 13.3 5.9
[Ru(η5-C5H5)(PPh3)2Tvt]
+ 4 51.4 18.1 21.0 9.5
Ru
Ph3P
Ph3P
L Ru
Ph3P
Ph3P
Cl +L
N
H
N
N
N
NH N
S
S
N S
S N
L = TzH (1)L = ImH (2)
L = Bzt (3)L = Tvt (4)
[PF6]
Scheme 1: Reaction scheme for the synthesis of the [Ru(η5-C5H5)(PPh3)2(L)][PF6] complexes 1–4 and the structures of the ligands L.
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Figure 1: Cyclic voltammogram of compound 2 in dichlorometh-
ane at sweep rate of 200mV/s.
studies carried out in dichloromethane suggests the possible
existence of Ru(III) analogues of compounds 1 and 2which
interest might be their potentiality as bio reductive prodrugs.
3.Biological Activity
3.1. Circular Dichroism. In Figures 2(a)–2(d), the circular
dichroism spectra of the compounds at several molar ratio
ruthenium complex DNA are showed. After 24 hours of
incubation at 37
◦C, changes in molar ellipticity can be
observed for the complexes 1, 2, 3,a n d4. These changes
in the wavelength and the ellipticity of free DNA indicate
modiﬁcations on the secondary structure of DNA as con-
sequence of the interaction of the complexes with DNA. In
spite of the substitution of ligands by N atoms of DNA bases
couldbepossible,themostprobablehypothesisistoconsider
weakinteractionsoftheligandswithDNAthroughhydrogen
bonds.
3.2. Atomic Force Microscopy (AFM). AFM pictures of DNA
pBR322, and DNA incubated with the complexes 1–4 are
shown in Figures 3–6.
The AFM image (Figure 3) corresponding to DNA
incubated with compound 1 in comparison with free DNA
shows typical modiﬁcations in the DNA forms, supercoiling,
kinksandcompaction.Compound2(Figure4)alsomodiﬁes
DNA forms, although the appearance of kinks is more
evident. In the case of compounds with the ligands Bzt
and Tvt, compounds 3 and 4 (Figures 5 and 6, resp.) the
interaction with DNA is stronger. In the case of compound
3, the ﬁrst image shows some DNA forms aﬀected by
supercoiling and kinks. In the two other images only a fewBioinorganic Chemistry and Applications 5
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Figure 2: Circular Dichroism spectra of ct-DNA incubated with the complexes at molar ratios 0.1, 0.3, and 0.5, at 37
◦C for 24 hours (a)
complex 1, (b) complex 2,( c )c o m p l e x3, and (d) complex 4.
forms can be observed but in them strong modiﬁcation can
be appreciated. Finally, in the case of compound 4, the image
shows several DNA forms with kinks and microfolds. These
modiﬁcations in comparison to the free pBR322 indicate
that the four compounds interact with DNA. Additional
measurements of the variation of viscosity with time at
constant temperature show a decreasing of the viscosity,
what allow us to conclude that there is not intercalation of
the ligands between base pairs of DNA. (See supplementary
material available online at doi: 10.1155/2010/963834.)
3.3. Electrophoretic Mobility. The inﬂuence of the com-
pounds on the tertiary structure of DNA was determined
by its ability to modify the electrophoretic mobility of the
covalently closed circular (ccc)a n do p e n( oc) forms of
pBR322 plasmid DNA. Figure 4 shows, from right to left, the6 Bioinorganic Chemistry and Applications
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Figure 3: AFM image of the (a) free plasmid pBR322 DNA, and (b) plasmid pBR322 DNA incubated with the complex [RuCp
(PPh3)2(TzH)][PF6] 1 ri = 0.5.
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Figure 4: AFM image of the plasmid pBR322 DNA incubated with
the complex [RuCp(PPh3)2(ImH)][PF6] 2 ri = 0.5.
mobility of the native pBR322 plasmid DNA and the plasmid
DNA incubated with cisplatin as a reference, and with the
compounds 1–4. The behavior of the gel electrophoretic
mobility of pBR322 plasmid and DNA ruthenium com-
pounds adducts show changes compatible with the AFM
images. In the pattern corresponding to the pBR322 plasmid
DNA (lane 6) a clean diﬀerence between the OC and CCC
bands can be observed. In lane 5, the typical coalescence
of the two bands for cisplatin is evident. In the zone
between OC and CCC bands in lanes 1–4 corresponding to
the DNA incubated with ruthenium complexes, new bands
(lane 4, compound 4) or one continuous band (lanes 1–
3, compounds 1–3) appear indicating the presence of DNA
f o r m sw i t hd i ﬀerent mobility in agarose gel.
3.4. Cytotoxicity of the Ruthenium Complexes against HL-60
Cells. The eﬀect of the ruthenium complexes was examined
on human leukaemia cancer cells (HL-60) using the MTT
assay, a colorimetric determination of cell viability during
in vitro treatment with a drug. The assay, developed as an
initial stage of drug screening, measures the amount of MTT
reductionbymitochondrial dehydrogenaseandassumesthat
cell viability (corresponding to the reductive activity) is
proportional to the production of purple formazan that
is measured spectrophotometrically. A low IC50 is desired
and implies cytotoxicity or antiproliferation at low drug
concentrations.
The drugs tested in this experiment were cisplatin,
[Ru(η5-C5H5)(PPh3)2TzH]+ 1,[Ru(η5-C5H5)(PPh3)2 ImH]+
2,[Ru(η5-C5H5)(PPh3)2 Bdt]+ 3,and[R u(η5-C5H5)(PPh3)2
Tvt]+ 4.
Cells were exposed to each compound continuously for
a 24 hours or a 72 hours period of time and then assayed
for growth using the MTT endpoint assay. Figure 8 shows
the dose-response curves of these drugs in terms of the drug
eﬀect on the growth of the HL-60 cells. The IC50 values of
complex 1,c o m p l e x2,c o m p l e x3,c o m p l e x4 and cisplatin
for the growth inhibition of HL-60 cells were summarized in
Table 2.
All of these ruthenium complexes exhibited antitumor
eﬀect against HL-60 cells. It was notable that complex 4
exerted the least potent eﬀect among all the complexes, but
this eﬀect is better than that of cisplatin at 24 hours and the
IC50 are very similar at 72 hours. The cytotoxicities displayed
by 1, 2,a n d3 were comparable with 3 slightly over 1 and 2.
3.5. Quantiﬁcation of Apoptosis by Annexin V Binding and
Flow Cytometry. We have also analysed by Annexin V-PI
ﬂow cytometry whether complexes 1, 2, 3,a n d4 a r ea b l et o
induce apoptosis in HL-60 cells after 24 hours of incubation
at equitoxic concentrations (IC50 values). Annexin V binds
phosphatidyl serine residues, which are asymmetrically dis-
tributed towards the inner plasma membrane but migrate to
the outer plasma membrane during apoptosis [30].
As it can be seen in Table 3, all metal complexes induce
cell death mainly by apoptosis. Complexes 1 and 2 areBioinorganic Chemistry and Applications 7
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Figure 5: Three AFM images (diﬀerent 2 × 2μm areas on mica sufarce) of the plasmid pBR322 DNA incubated with the complex
[RuCp(PPh3)2(Bzt)][PF6] 3 ri = 0.5.
less toxic than complexes 3 and 4, the ﬁrst two complexes
induced less necrotic or damage cells at IC50 treatment.
4. Conclusion
The complexes were tested for potential antitumor activity
against the human promyelocytic leukemia cell line HL-
60 using a MTT assay. The four complexes tested possess
excellent antitumor activities, with IC50 values lower than
that of cisplatin. It cannot be discarded that one of the
targets of the antitumor process would be the DNA, because
interaction of the four compounds with DNA(ct-DNA or
pBR322 plasmid DNA) has been demonstrated by CD,
Electrophoretic mobility, and AFM studies.
5. ExperimentalProtocols
All the syntheses were carried out under dinitrogen atmo-
sphere using current Schlenk techniques and the solvents
used were dried using standard methods [31]. The starting
material [Ru(η5-C5H5)(PPh3)2Cl] was prepared following
the method described in the literature [27]. Compounds
[RuCp(PPh3)2(Bzt)][PF6] 3 and [RuCp(PPh3)2(Tvt)][PF6]
4 were previously characterised [25, 26]. FT-IR spectra were
recorded in a Mattson Satellite FT-IR spectrophotometer
with KBr pellets; only signiﬁcant bands are cited in text.
1H-, 13C-, and 31P-NMR spectra were recorded on a
Bruker Advance 400 spectrometer at probe temperature.
The 1Ha n d13C chemical shifts are reported in parts
per million (ppm) downﬁeld from internal Me4Si and the
31P NMR spectra are reported in ppm downﬁeld from
external standard, 85% H3PO4. Elemental analyses were
obtained at Laborat´ orio de An´ alises, Instituto Superior
T´ ecnico, using a Fisons Instruments EA1108 system. Data
acquisition, integration and handling were performed using
a PC with the software package EAGER-200 (Carlo Erba
Instruments). Electronic spectra were recorded at room
temperature on a Jasco V-560 spectrometer in the range of
200–900nm.8 Bioinorganic Chemistry and Applications
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Figure 6: AFM image of the plasmid pBR322 DNA incubated with
the complex [RuCp(PPh3)2(Tvt)][PF6] 4 ri = 0.5.
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Figure 7: Agarose gel electrophoretic mobility of DNA pBR322
treated with compounds 1 (lane 1); compound 2 (lane 2);
compound 3 (lane 3); compound 4 (lane 4); cisplatin (lane 5) and
DNA pBR322 (lane 6).
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Figure 8: Inhibitory eﬀects of complexes 1, 2, 3 and 4 on tumor cell
proliferation in vitro.
5.1. Synthesis of [CpRu(PPh3)2(TzH)][PF6]( 1 ) .
N
N
NH N
1
2
3
4
5
6
1 
To a suspension of [CpRu(PPh3)2Cl] (0.73g; 1mmol)
in THF : CH2Cl2 (3 : 1) was added 5-phenyl-1H-tetrazole
(0.15g; 1.1mmol) followed by the addition of TlPF6 (0.35g;
1mmol). The orange mixture was slightly warmed at 35
◦C
during 30 minutes and turned yellow. The precipitate of
TlCl was removed by cannula-ﬁltration and the solvent
evaporated. The yellow oil residue was treated with n-
hexane and the obtained solid was recrystallized from
dichloromethane/ethyl ether. Yield: 80 %.
1H NMR [CDCl3,M e 4Si, δ/ppm]: 7.70 [d,2 ,H 2 +
H6(TzH); J2,6= 7.7Hz]; 7.50–7.44 [m, 3, H3 +H 4+
H5(TzH)]; 7.35 [t,6 ,H para (PPh3)]; 7.24 [t, 12, Hmeta
(PPh3)]; 7.17 [d, 12, Horto (PPh3)] ;4 . 4 6[ s,5 , ηη5-C5H5].
13CN M R[ C D C l 3, δ/ppm]: 156.95 (C1, TzH); 136.82
(Cq,PPh3);134.07(C4,TzH);132.16(CH,PPh3);130.26(C3
+C 5, TzH); 129.70 (CH, PPh3); 125.45 (CH, PPh3); 128.07
(C2 +C 6, TzH); 127.72 (C1, TzH); 83.47 (C5H5).
31P NMR [CDCl3, δ/ppm]: 41.9 [s, PPh3]; −144.1 [sept,
PF6
−].
FT-IR [KBr, cm−1]: 3057 (wm); 2984 (w); 2913 (w);
2836 (w); 2760 (w); 2699 (w); 2609 (wm); 2550 (w); 2481
(w); 1608 (w); 1563 (wm); 1481 (m); 1434 (ms); 1410 (m);
1312 (w); 1185 (w); 1163 (w); 1089 (ms); 997 (m); 840
(s); 745 (ms); 697 (s); 557 (ms); 521 (S); 496 (ms); UV-
Vis. in CH2Cl2, λmax /nm (ε/M−1cm−1): 250 (21176), 348
(7603); Elem. Anal. Found: C 58.93; H 4.21; N 5.70; Calc.
for C48H41N4P3F6Ru; C, 58.72; H, 4.21; N, 5.71.
5.2. Synthesis of [CpRu(PPh3)2(ImH)][PF6]( 2 ) .
N NH
1
2
3
4 5
To a solution of [CpRu(PPh3)2Cl] (0.20g; 0.275mmol)
in dichloromethane (25mL), imidazole was added (0.02g;
0.3mmol) followed by the addition of TlPF6 (0.11g;
0.3mmol). The reaction was carried out at room tempera-
ture with vigorous stirring during 14 hours with the change
of colour from orange to yellow. The precipitate of TlCl was
removed by cannula-ﬁltration and the solvent evaporated.
The product was washed with n-hexane and recrystallized
from dichloromethane/ethyl ether. Yield: 70%.
1H NMR [(CD3)2CO, Me4Si,δ/ppm]: 11.53 [s, 1,
NH(Im)];7.46[t,6,H para (PPh3)];7.37[t,12,Hmeta (PPh3)];
7.23 [d, 12, Hortho (PPh3)]; 4.57 [s,5 ,η5-C5H5], H2 +H 4 +
H5 (Im) obscured by PPh3.13C NMR [(CD3)2CO, δ/ppm]:
144.2 (C2, Im); 135.5 (C4 +C5, Im); 133.61 (PPh3); 133.55
(PPh3); 133.50 (PPh3); 130.0 (PPh3); 128.42 (PPh3); 128.38Bioinorganic Chemistry and Applications 9
(PPh3); 128.33; 117.8 (Im); 82.6 (Cp); 31P NMR [(CD3)2CO,
δ/ppm]: 42.04 (s, PPh3); −144.04 (sept,P F 6
−).
FT-IR [KBr, cm−1]: 3056 (w); 2955 (w); 1480 (m); 1434
(s); 1089 (m); 999 (w); 840 (s); 745 (s); 696 (S); 557 (s); 522
(s).
UV-Vis. in CH2Cl2, λmax/nm (ε/M−1cm−1): 248 (21200),
273(8162),348(3285);Elem.Anal.Found:C,58.19;H,4.68;
N, 3.16. Found for C44H39N2P3F6Ru: C, 58.47; H, 4.35; N,
3.10.
5.3. Electrochemical Experiments. Cyclic voltammograms of
ligands and complexes were obtained using a EG and
G Princeton Applied Research Model 273A potentio-
stat/galvanostat monitored with a personal computer loaded
with Electrochemistry PowerSuite v2.51 software from
Princeton Applied Research at room temperature. A three-
electrode conﬁguration small capacity cell was equipped
with a platinum-disk working electrode (1.0mm diameter),
a silver-wire pseudo-reference electrode connected by a
Lugging capillary and a platinum wire auxiliary electrode.
The electrochemical experiments were performed in 0.2M
solutions of TBAPF6 in dichloromethane or acetonitrile,
under a nitrogen atmosphere and the redox potentials were
measuredusingferroceneastheinternalstandard.Theredox
potential values were quoted relative to the SCE by using
the ferrocenium/ferrocene redox couple (Ep/2 = 0.46 or
0.40V versus SCE for dichloromethane or acetonitrile, resp.)
[32].
The supporting electrolyte was purchased from Aldrich
Chemical Co., recrystallized from ethanol, washed with
diethyl ether and dried under vacuum at 110
◦Cf o r2 4
hours. Reagent grade acetonitrile and dichloromethane were
dried over P4O10 and CaH2, respectively, and distilled under
nitrogen atmosphere before use.
5.4. Biological Assays
5.4.1. DNA Interaction Studies
Circular Dichroism. All compounds were dissolved in an
aqueous solution (prepared with milli-Q water) of 4%
DMSO (2 mg compound/5mL). The stock solutions were
freshly prepared before use. The samples were prepared by
addition of aliquots of these stock solutions to the appro-
priate volume of Calf Thymus DNA in a TE buﬀer solution
(50mM NaCl, 10mM tris-(hydroxymethyl)aminomethane
hydrochloride (Tris-HCl), 0.1mM H4edta, pH 7.4) (5mL).
The amount of complex added to the DNA solution was
designated as ri (the input molar ratio of Ru to nucleotide
and it is calculated with formula
ri =
m ×Mnucl ×Am
C ×Mr ×V
,( 1 )
where m = mass of the compound (μg); Mnucl = medium
nuclear mass per nucleotide (330g/mol); C = concentration
of the DNA solution (μg/ml); Mr = molecular mass of each
compound (g/mol); V = t o t a lv o l u m eo fe a c hs a m p l e( 5m L ) .
Asablank, asolution in TEoffreenativeDNAwasused.The
CD spectra of DNA in the presence or absence of complexes
(DNA concentration 20μg/mL, molar ratios ri = 0.10, 0.30,
0.50) were recorded at room temperature, after 24 hours
incubation at 37
◦C, on a JASCO J-720 spectropolarimeter
with a 450W xenon lamp using a computer for spectral
subtraction and noise reduction. Each sample was scanned
twice in a range of wavelengths between 220 and 330nm.
The CD spectra drawn are the average of three independent
scans. The data are expressed as average residue molecular
ellipticity (θ)i nd e g r e e s ·cm2·dmol−1.
Viscosity Measurements. Viscosity experiments were carried
out with an AND-SV-1 viscometer in a water bath using a
water jacket accessory and maintained the constant temper-
ature at 25
◦C. A range of 200–370μL of 5mM solutions of
the diﬀerent compounds were added in 2mL of 100mM ct-
DNA solution. The ﬂow time was measured by a digital stop
watch.
Atomic Force Microscopy (TMAFM). DNA pBR322 was
heated at 60
◦ for 10 minutes to obtain OC form. Stock
solution was 1mg/mL in a buﬀer solution of HEPES (4
mM Hepes, pH 7.4/2mM MgCl2). Each sample contained
1μL of DNA pBR322 of concentration 0.25μg/μLf o ra
ﬁnal volume of 40μL. The amount of drug added is also
expressed as ri. AFM samples were prepared by casting a
3-μL drop of test solution onto freshly cleaved Muscovite
green mica disks as the support. The drop was allowed to
stand undisturbed for 3 minutes to favour the adsorbate-
substrate interaction. Each DNA-laden disk was rinsed with
Milli-Q water and was blown dry with clean compressed
argon gas directed normal to the disk surface. Samples
were stored over silica prior to AFM imaging. All Atomic
Force Microscopy (AFM) observations were made with
a Nanoscope III Multimode AFM (Digital Instrumentals,
Santa Barbara, CA). Nano-crystalline Si cantilevers of 125-
nm length with a spring constant of 50N/m average ended
with conical-shaped Si probe tips of 10-nm apical radius and
cone angle of 35◦ were utilized. High-resolution topographic
AFM images were performed in air at room temperature
(relative humidity < 40%) on diﬀerent specimen areas of
2 × 2μm operating in intermittent contact mode at a rate of
1–3Hz.
Gel Electrophoresis of Ruthenium Complexes-pBR322. pBR
322 DNA aliquots (0.25μg/mL) were incubated in TE buﬀer
(10mM Tris.HCl, 1mM EDTA, pH = 7,5) at molar ratio
ri = 0.50 for electrophoresis study. Incubation was carried
out in the dark at 37
◦C for 24 hours. 4μL of charge marker
were added to aliquots parts of 20μL of the compound-DNA
complex.Themixturewaselectrophoresedinagarosegel(1%
in TBE buﬀer, Tris-Borate-EDTA) for 5 hours at 1.5V/cm.
Afterwards, the DNA was dyed with ethydium bromide
solution (0.75μg/mL in TBE) for 6 hours. A sample of free
DNA was used as control. The experiment was carried out in
an ECOGEN horizontal tank connected to a PHARMACIA
GPS 200/400 variable potential power supply and the gel
was photographed with an image Master VDS, Pharmacia
Biotech.10 Bioinorganic Chemistry and Applications
5.5. Tumor Cell Lines and Culture Conditions. The cell line
used in this experiment was the human acute promyelocytic
leukaemia cell line HL-60 (American Type Culture Collec-
tion (ATCC)). Cells were routinely maintained in RPMI-
1640 medium supplemented with 10%(v/v) heat inactivated
foetal bovine serum, 2mmol/L glutamine, 100U/mL peni-
cillin, and 100μg/mL streptomycin (Gibco BRL, Invitrogen
Corporation, Netherlands) in a highly humidiﬁed atmo-
sphere of 95% air with 5% CO2 at 37
◦C.
Cytotoxicity Assays. Growth inhibitory eﬀect of ruthenium
complexes on the leukaemia HL-60 cell line was measured by
the microculture tetrazolium, [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, MTT] assay [33]. Brieﬂy,
cells growing in the logarithmic phase were seeded in 96-
well plates (104 cells per well), and then were treated with
varying doses of ruthenium complexes and the reference
drug cisplatin at 37
◦C for 24 or 72 hours. For each of the
variants tested, four wells were used. Aliquots of 20μLo f
MTT solution were then added to each well. After 3 hours,
the colour formed was quantiﬁed by a spectrophotometric
plate reader at 490nm wavelength. The percentage cell
viability was calculated by dividing the average absorbance
of the cells treated with a platinum complex by that of the
control; IC50 values (drug concentration at which 50% of
the cells are viable relative to the control) were obtained by
GraphPad Prism software, version 4.0.
In Vitro Apoptosis Assay. Induction of apoptosis in vitro by
ruthenium compounds was determined by a ﬂow cytometric
assay with Annexin V-FITC by using an Annexin V-FITC
Apoptosis Detection Kit (Roche) [30]. Exponentially grow-
ing HL-60 cells in 6-well plates (5 × 105 cells/well) were
exposedtoconcentrationsequaltotheIC50 oftheruthenium
drugs for 24 hours. Afterwards, the cells were subjected to
staining with the Annexin V-FITC and propidium iodide.
The amount of apoptotic cells was analyzed by ﬂow cytome-
try (BD FACSCalibur).
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